Product Description
ARV-393 is an investigational PROTAC® designed to degrade B-cell lymphoma 6 protein (BCL6) which is a transcriptional repressor implicated in B cell lymphomas by facilitating B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage response. PROTAC®-mediated degradation would address the scaffolding function of BCL6. BCL6 has completed investigational new drug (IND)-enabling studies. (Sourced from: https://www.arvinas.com/research-and-development/pipeline/)
Mechanisms of Action: BCL6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Arvinas Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Immunoblastic Lymphadenopathy|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|T-Cell Peripheral Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ARV-393-101 | P1 |
Not yet recruiting |
Immunoblastic Lymphadenopathy|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|T-Cell Peripheral Lymphoma |
2025-12-01 |